DK1496895T3 - Anvendelse af cyclopamin til behandling af psoriasis og andre hudlidelser - Google Patents

Anvendelse af cyclopamin til behandling af psoriasis og andre hudlidelser

Info

Publication number: DK1496895T3
Authority: DK; Denmark
Prior art keywords: cyclopamine; treatment; corticosteroid; skin; lesions
Prior art date: 2002-04-19

Application number

DK03723620T

Other languages

English (en)

Inventor

Sinan Tas

Oktay Avci

Original Assignee

Sinan Tas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-19

Filing date

2003-03-17

Publication date

2006-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29247069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1496895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-19 Priority claimed from PCT/TR2002/000017 external-priority patent/WO2002078704A1/en

2003-03-17 Application filed by Sinan Tas filed Critical Sinan Tas

2006-03-27 Application granted granted Critical

2006-03-27 Publication of DK1496895T3 publication Critical patent/DK1496895T3/da

Links

QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 title abstract 5
QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 title abstract 5
201000004681 Psoriasis Diseases 0.000 title abstract 2
208000017520 skin disease Diseases 0.000 title 1
239000003246 corticosteroid Substances 0.000 abstract 3
230000003902 lesion Effects 0.000 abstract 2
230000001185 psoriatic effect Effects 0.000 abstract 2
210000003491 skin Anatomy 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
229930013930 alkaloid Natural products 0.000 abstract 1
150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
230000024245 cell differentiation Effects 0.000 abstract 1
230000008034 disappearance Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
210000002615 epidermis Anatomy 0.000 abstract 1
210000004969 inflammatory cell Anatomy 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000002203 pretreatment Methods 0.000 abstract 1
231100000444 skin lesion Toxicity 0.000 abstract 1
206010040882 skin lesion Diseases 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Birds (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK03723620T 2002-04-19 2003-03-17 Anvendelse af cyclopamin til behandling af psoriasis og andre hudlidelser DK1496895T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/TR2002/000017 WO2002078704A1 (en)	2001-07-02	2002-04-19	Use of cyclopamine in the treatment of psoriasis

Publications (1)

Publication Number	Publication Date
DK1496895T3 true DK1496895T3 (da)	2006-03-27

Family

ID=29247069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03723620T DK1496895T3 (da)	2002-04-19	2003-03-17	Anvendelse af cyclopamin til behandling af psoriasis og andre hudlidelser

Country Status (15)

Country	Link
US (6)	US7605167B2 (da)
EP (2)	EP1411938B1 (da)
JP (1)	JP2006512281A (da)
KR (4)	KR20080096605A (da)
CN (2)	CN101642458A (da)
AT (1)	ATE309802T1 (da)
AU (1)	AU2003230541B2 (da)
BR (1)	BR0309396A (da)
CA (3)	CA2452152A1 (da)
DE (1)	DE60302348T2 (da)
DK (1)	DK1496895T3 (da)
EA (1)	EA200401355A1 (da)
ES (1)	ES2253672T3 (da)
MX (1)	MXPA04010294A (da)
WO (1)	WO2003088964A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7291626B1 (en)	1998-04-09	2007-11-06	John Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60028411T2 (de)	1999-10-13	2007-01-04	Johns Hopkins University School Of Medicine	Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US8044259B2 (en)	2000-08-03	2011-10-25	The Regents Of The University Of Michigan	Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en)	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
CA2452152A1 (en) *	2001-07-02	2002-10-10	Sinan Tas	Use of cyclopamine in the treatment of psoriasis
US20170326118A1 (en) *	2001-07-02	2017-11-16	Sinan Tas	Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
BR0117063A (pt) *	2001-07-02	2004-07-27	Sinan Tas	Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
ES2578728T3 (es) *	2004-08-27	2016-07-29	Infinity Pharmaceuticals, Inc.	Proceso para la preparación de compuestos análogos de ciclopamina
WO2006039569A1 (en) *	2004-09-30	2006-04-13	The University Of Chicago	Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2500360B1 (en)	2005-10-31	2015-08-05	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
US20090156611A1 (en) *	2005-11-11	2009-06-18	Licentia Ltd.	Mammalian hedgehog signaling modulators
WO2008121102A2 (en) *	2006-02-21	2008-10-09	The Regents Of The University Of Michigan	Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) *	2006-03-24	2007-11-01	Infinity Pharmaceuticals, Inc.	Dosing regimens for the treatment of cancer
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en)	2007-01-24	2014-11-12	The Regents of the University of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
CN101687877B (zh)	2007-03-07	2014-07-23	无限发现股份有限公司	杂环环杷明类似物及其使用方法
EP2134719B1 (en) *	2007-03-07	2013-07-17	Infinity Discovery, Inc.	Cyclopamine lactam analogs and methods of use thereof
US20100297118A1 (en) *	2007-12-27	2010-11-25	Macdougall John	Therapeutic Cancer Treatments
WO2009086451A1 (en) *	2007-12-27	2009-07-09	Infinity Pharmaceuticals, Inc.	Methods for stereoselective reduction
JP2011522773A (ja) *	2007-12-27	2011-08-04	インフィニティファーマスーティカルズ、インク．	治療剤での癌の処置方法
WO2009099625A2 (en) *	2008-02-08	2009-08-13	The Board Of Regents Of The University Of Texas System	Cyclopamine tartrate salt and uses thereof
GB0813740D0 (en) *	2008-07-28	2008-09-03	Angeletti P Ist Richerche Biologica	Therapeutic compounds
EP2331136B1 (en)	2008-09-26	2018-01-10	OncoMed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
US20110275576A1 (en) *	2009-01-06	2011-11-10	Utah State University	Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
GB0900484D0 (en)	2009-01-13	2009-02-11	Angeletti P Ist Richerche Bio	Therapeutic agent
CA2769795C (en)	2009-08-05	2020-01-07	Infinity Pharmaceuticals, Inc.	Enzymatic transamination of cyclopamine analogs
GB0916608D0 (en)	2009-09-22	2009-11-04	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2011057222A1 (en) *	2009-11-06	2011-05-12	Infinity Pharmaceuticals, Inc.	Oral formulations of a hedgehog pathway inhibitor
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088404A1 (en) *	2010-01-15	2011-07-21	Infinity Pharmaceuticals , Inc	Treatment of fibrotic conditions using hedgehog inhibitors
CN102971337B (zh)	2010-04-01	2016-09-21	昂考梅德药品有限公司	卷曲蛋白结合药剂及其应用
US9376447B2 (en)	2010-09-14	2016-06-28	Infinity Pharmaceuticals, Inc.	Transfer hydrogenation of cyclopamine analogs
JP2015536933A (ja)	2012-10-23	2015-12-24	オンコメッドファーマシューティカルズインコーポレイテッド	Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
CN105073195A (zh)	2013-02-04	2015-11-18	昂科梅德制药有限公司	使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en)	2013-03-14	2015-10-27	Oncomed Pharmaceuticals, Inc.	MET-binding agents and uses thereof
BR112017026103B1 (pt)	2015-06-04	2023-10-03	Sol-Gel Technologies Ltd	Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2018129364A1 (en)	2017-01-06	2018-07-12	Palvella Therapeutics Llc	Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US11424772B2 (en)	2018-12-06	2022-08-23	Berex, Inc.	Receiver architectures with parametric circuits
EP4358955A4 (en) *	2021-06-21	2025-01-08	Palvella Therapeutics, Inc.	Methods and compositions for treating gorlin syndrome
CA3227688A1 (en)	2021-09-13	2023-03-02	Sinan Tas	Effective interventions with aging and diseases of aging of human and their consequences

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT73772B (en) *	1980-10-06	1983-10-14	Glaxo Group Ltd	Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US5891465A (en) *	1996-05-14	1999-04-06	Biozone Laboratories, Inc.	Delivery of biologically active material in a liposomal formulation for administration into the mouth
CA2280736C (en)	1997-02-10	2012-05-29	The President And Fellows Of Harvard College	Methods for modulating hematopoiesis and vascular growth
US7741298B2 (en) *	1997-06-20	2010-06-22	New York University	Method and compositions for inhibiting tumorigenesis
US20050130922A1 (en) *	1997-06-20	2005-06-16	Altaba Ariel R.I.	Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) *	1997-06-20	2001-05-29	New York University	Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7291626B1 (en) *	1998-04-09	2007-11-06	John Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) *	1998-04-09	2005-03-15	Johns Hopkins University School Of Medicine	Inhibitors of hedgehog signal pathways, compositions and uses related thereto
JP5067986B2 (ja) *	1998-04-09	2012-11-07	ジョンズホプキンズユニヴァーシティースクールオブメディシン	ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
US6432970B2 (en) *	1998-04-09	2002-08-13	Johns Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6291516B1 (en)	1999-01-13	2001-09-18	Curis, Inc.	Regulators of the hedgehog pathway, compositions and uses related thereto
GB0013674D0 (en) *	1999-06-08	2000-07-26	Lorantis Ltd	Therapeutic use
US20050080138A1 (en) *	1999-09-16	2005-04-14	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60028411T2 (de) *	1999-10-13	2007-01-04	Johns Hopkins University School Of Medicine	Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) *	1999-10-14	2003-04-22	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2392958A1 (en) *	1999-11-30	2001-06-07	Curis, Inc.	Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) *	1999-11-30	2005-10-04	Curis, Inc.	Methods and compositions for regulating lymphocyte activity
US6683108B1 (en) *	2000-03-30	2004-01-27	Curis, Inc.	Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) *	2000-03-30	2006-10-03	Curis, Inc.	Small organic molecule regulators of cell proliferation
US7498304B2 (en) *	2000-06-16	2009-03-03	Curis, Inc.	Angiogenesis-modulating compositions and uses
CA2412215A1 (en) *	2000-06-16	2001-12-27	Curis, Inc.	Angiogenesis-modulating compositions and uses
CU23175A1 (es) *	2000-07-17	2006-09-22	Ct De Investigacion Y Desarrol	Formulacion liposomica de propionato de clobetasol
US20020165221A1 (en) *	2000-10-13	2002-11-07	Baxter Anthony David	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7708998B2 (en) *	2000-10-13	2010-05-04	Curis, Inc.	Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
ES2623711T3 (es) *	2000-10-13	2017-07-12	Curis, Inc.	Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
AU2002247847A1 (en)	2001-04-09	2002-10-21	Lorantis Limited	Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
BR0117063A (pt) *	2001-07-02	2004-07-27	Sinan Tas	Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
CA2452152A1 (en) *	2001-07-02	2002-10-10	Sinan Tas	Use of cyclopamine in the treatment of psoriasis
BR0213100A (pt) *	2001-10-05	2004-11-30	Combinatorx Inc	Combinações para o tratamento de distúrbios imuniinflamatórios
US6927205B2 (en) *	2003-04-28	2005-08-09	Procyte Corporation	Compositions and methods for treatment of psoriasis
KR20050037103A (ko)	2003-10-17	2005-04-21	주식회사 엘지생활건강	피부 미백용 화장료 조성물
ES2578728T3 (es) *	2004-08-27	2016-07-29	Infinity Pharmaceuticals, Inc.	Proceso para la preparación de compuestos análogos de ciclopamina
AU2006283040B2 (en) *	2005-08-22	2011-08-25	The Johns Hopkins University	Hedgehog pathway antagonists to treat disease

2002
- 2002-04-19 CA CA002452152A patent/CA2452152A1/en not_active Abandoned
- 2002-04-19 EP EP02736467A patent/EP1411938B1/en not_active Expired - Lifetime
2003
- 2003-03-17 KR KR1020087024138A patent/KR20080096605A/ko not_active Ceased
- 2003-03-17 EP EP03723620A patent/EP1496895B1/en not_active Expired - Lifetime
- 2003-03-17 ES ES03723620T patent/ES2253672T3/es not_active Expired - Lifetime
- 2003-03-17 KR KR1020077025034A patent/KR20070108287A/ko not_active Ceased
- 2003-03-17 AT AT03723620T patent/ATE309802T1/de not_active IP Right Cessation
- 2003-03-17 CN CN200910146214A patent/CN101642458A/zh active Pending
- 2003-03-17 DK DK03723620T patent/DK1496895T3/da active
- 2003-03-17 JP JP2003585716A patent/JP2006512281A/ja active Pending
- 2003-03-17 CN CNA038087847A patent/CN1835748A/zh active Pending
- 2003-03-17 WO PCT/TR2003/000017 patent/WO2003088964A1/en not_active Ceased
- 2003-03-17 KR KR1020087024137A patent/KR20080094739A/ko not_active Ceased
- 2003-03-17 KR KR10-2004-7016679A patent/KR20040102117A/ko not_active Ceased
- 2003-03-17 DE DE60302348T patent/DE60302348T2/de not_active Expired - Lifetime
- 2003-03-17 EA EA200401355A patent/EA200401355A1/ru unknown
- 2003-03-17 BR BR0309396-4A patent/BR0309396A/pt not_active IP Right Cessation
- 2003-03-17 MX MXPA04010294A patent/MXPA04010294A/es active IP Right Grant
- 2003-03-17 CA CA2636960A patent/CA2636960C/en not_active Expired - Fee Related
- 2003-03-17 AU AU2003230541A patent/AU2003230541B2/en not_active Ceased
- 2003-03-17 CA CA2481499A patent/CA2481499C/en not_active Expired - Fee Related
- 2003-10-09 US US10/682,662 patent/US7605167B2/en not_active Expired - Fee Related
- 2003-10-09 US US10/682,584 patent/US7893078B2/en not_active Expired - Fee Related
2007
- 2007-10-18 US US11/874,653 patent/US7629352B2/en not_active Expired - Fee Related
- 2007-10-18 US US11/874,631 patent/US8025893B2/en not_active Expired - Fee Related
2009
- 2009-07-22 US US12/460,620 patent/US9757361B2/en not_active Expired - Fee Related
2011
- 2011-01-13 US US12/930,677 patent/US20110104254A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2636960A1 (en)	2003-10-30
CN1835748A (zh)	2006-09-20
KR20070108287A (ko)	2007-11-08
DE60302348D1 (de)	2005-12-22
ATE309802T1 (de)	2005-12-15
BR0309396A (pt)	2005-02-09
US20080089915A1 (en)	2008-04-17
MXPA04010294A (es)	2005-05-17
CN101642458A (zh)	2010-02-10
US20040072913A1 (en)	2004-04-15
CA2452152A1 (en)	2002-10-10
CA2481499C (en)	2013-05-21
US20110104254A1 (en)	2011-05-05
KR20040102117A (ko)	2004-12-03
US7629352B2 (en)	2009-12-08
JP2006512281A (ja)	2006-04-13
EP1496895A1 (en)	2005-01-19
EP1411938B1 (en)	2005-07-06
AU2003230541A1 (en)	2003-11-03
US20080090790A1 (en)	2008-04-17
US20040072914A1 (en)	2004-04-15
WO2003088964A1 (en)	2003-10-30
US20090286822A1 (en)	2009-11-19
KR20080096605A (ko)	2008-10-30
ES2253672T3 (es)	2006-06-01
EA200401355A1 (ru)	2005-06-30
CA2481499A1 (en)	2003-10-30
US7605167B2 (en)	2009-10-20
US8025893B2 (en)	2011-09-27
AU2003230541B2 (en)	2006-06-29
US20100048725A2 (en)	2010-02-25
US7893078B2 (en)	2011-02-22
US9757361B2 (en)	2017-09-12
DE60302348T2 (de)	2006-07-27
CA2636960C (en)	2013-12-31
KR20080094739A (ko)	2008-10-23
EP1496895B1 (en)	2005-11-16
EP1411938A1 (en)	2004-04-28

Publication	Publication Date	Title
EA200401355A1 (ru)	2005-06-30	Применение циклопамина при лечении псориаза и других кожных заболеваний
MXPA05013075A (es)	2006-03-17	Inhibidores de p-38 basados en heterociclo de 5 miembros.
Gobello et al.	2003	Medium-versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study
MXPA05013824A (es)	2006-02-28	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
NO20031019D0 (no)	2003-03-05	Vedvarende frigivelsesformuleringer av oksymorfon
TR201903587T4 (tr)	2019-04-22	Telomeraz aktivitesinin artırılması için bileşimler.
DE602004025504D1 (de)	2010-03-25	Bicyclische heterocyclische p-38-kinase-inhibitoren
WO2003068171A3 (en)	2003-09-25	Method and composition for treatment of inflammation and aids-associated neurological disorders
CY1111433T1 (el)	2015-08-05	Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
DK1539166T3 (da)	2008-10-20	Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
BR0209922A (pt)	2004-07-27	Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
EA200001044A2 (ru)	2001-12-24	Соединения для лечения женской сексуальной дисфункции
Joseph et al.	2005	Unilateral remission of psoriasis following traumatic nerve palsy
DK1551409T3 (da)	2007-06-11	Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
EP1543158A4 (en)	2007-06-06	REGULATED APTAMER THERAPEUTICS
DE69818939D1 (de)	2003-11-20	Rosaceae extrakt als bradykinin-antagonist
DE60140960D1 (de)	2010-02-11	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY134562A (en)	2007-12-31	Methods and compositions to treat conditions associated with neovascularization
WO2003056899A3 (en)	2003-11-27	Nitric oxide donors for treatment of disease and injury
DK1289534T3 (da)	2006-03-20	Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser
DK0817646T3 (da)	2003-04-22	Fremgangsmåder til behandling af inflammation og præparater derfor
ATE556134T1 (de)	2012-05-15	Mesenchymstammzellen und verwendungendafür
DK1596879T3 (da)	2011-04-11	Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
BRPI0416202A (pt)	2006-12-26	formulações inibidoras de fosfodiesterase v
IL165323A (en)	2015-05-31	Compounds that eliminate a 2 g checkpoint in the cell cycle that is attracted by DNA damage And / or aiding anti-cancer activity of DNA-damaging treatments